Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Robson

Showing results (111-120 of 218) with videos related to

Pageof 22
Sort By:
NPJ Breast Cancer|October 2, 2025
Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancerNour Abuhadra, Fresia Pareja, Charlie White, et al.
JAMA Network Open|July 2, 2020
Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer GenesShannon Gallagher, Elisha Hughes, Susanne Wagner, et al.
Breast Cancer Research and Treatment|March 7, 2012
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effortSerena Masciari, Deborah A Dillon, Michelle Rath, et al.
NPJ Breast Cancer|October 18, 2024
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
Research Square|May 15, 2024
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast CancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
JCO Precision Oncology|September 14, 2020
Pathogenic Loss-of-Function Germline <i>TERT</i> Mutations in Patients With Solid TumorsMichael F Walsh, Rosalba Sacca, Temima Wildman, et al.
Journal of the National Cancer Institute|October 16, 2003
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemiaKenneth Offit, Orna Levran, Brian Mullaney, et al.
Plos One|July 11, 2013
Assessment of SLX4 Mutations in Hereditary Breast CancersSohela Shah, Yonghwan Kim, Irina Ostrovnaya, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 2019
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trialMark Robson, Kathryn J Ruddy, Seock-Ah Im, et al.
Pageof 22

Showing results (111-120 of 218) with videos related to

Sort By:
Pageof 22
NPJ Breast Cancer|October 2, 2025
Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancerNour Abuhadra, Fresia Pareja, Charlie White, et al.
JAMA Network Open|July 2, 2020
Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer GenesShannon Gallagher, Elisha Hughes, Susanne Wagner, et al.
Breast Cancer Research and Treatment|March 7, 2012
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effortSerena Masciari, Deborah A Dillon, Michelle Rath, et al.
NPJ Breast Cancer|October 18, 2024
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
Research Square|May 15, 2024
Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast CancerNicholas Mai, Carlos H Dos Anjos, Pedram Razavi, et al.
JCO Precision Oncology|September 14, 2020
Pathogenic Loss-of-Function Germline <i>TERT</i> Mutations in Patients With Solid TumorsMichael F Walsh, Rosalba Sacca, Temima Wildman, et al.
Journal of the National Cancer Institute|October 16, 2003
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemiaKenneth Offit, Orna Levran, Brian Mullaney, et al.
Plos One|July 11, 2013
Assessment of SLX4 Mutations in Hereditary Breast CancersSohela Shah, Yonghwan Kim, Irina Ostrovnaya, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 2019
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trialMark Robson, Kathryn J Ruddy, Seock-Ah Im, et al.
Pageof 22